Advertisement

Dyspareunia in Women: Updates in Mechanisms and Current/Novel Therapies

  • Salvatore CarusoEmail author
  • Caterina Monaco
Female Sexual Dysfunction and Disorders (T Lorenz and R Nappi, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Female Sexual Dysfunction and Disorders
  2. Topical Collection on Female Sexual Dysfunction and Disorders

Abstract

Purpose of Review

Dyspareunia could influence negatively the sexuality of pre- and postmenopausal women. Genital pain can be cause for disturbing sexual desire. We conducted a review to describe interventions to address dyspareunia.

Recent Findings

We reviewed 64 articles, based on studies concerning definitions of dyspareunia, genital sexual pain, different causes in pre/postmenopausal women, physical examination, management by age groups, and current/novel therapies. Evidence was drawn from systematic reviews of randomized controlled trials, clinical controlled studies, and case-control-studies, and from non-systematic reviews.

Summary

All included studies showed a significant reduction of dyspareunia after specific treatment. Women who received hormonal or non-hormonal medication, or physical therapy, had a better quality of sexual life. Hormonal and physical therapies show faster efficacy than non-hormonal therapies. In addition, pharmacological, psychological, and sexological integrated therapies seem to be more effective than single treatments.

Keywords

Dyspareunia Endometriosis Estrogen therapy Female sexual disorders Genital sexual pain Genitourinary syndrome Hormonal-non hormonal therapies Ospemifene 

Notes

Acknowledgements

The authors wish to thank the Scientific Bureau of the University of Catania for language support.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Barbara G, Facchin F, Buggio L, Somigliana E, Berlanda N, Kustermann A, et al. What is known and unknown about the association between endometriosis and sexual functioning: a systematic review of the literature. Reprod Sci. 2017;24:1566–76 The ideal treatment for endometriosis-related sexual dysfunctions should be conducted by a multidisciplinary team composed of gynecologists, sexologists, and psychologists /psychotherapists. CrossRefGoogle Scholar
  2. 2.
    Khandker M, Brady SS, Vitonis AF, Maclehouse RF, Stewart EG, Harlow BL. The influence of depression and anxiety on risk of adult onset vulvodynia. J Women's Health. 2011;20:1445–51.CrossRefGoogle Scholar
  3. 3.
    Binik YM. The DSM diagnostic criteria for dyspareunia. Arch Sex Behav. 2010;39:292–303.CrossRefGoogle Scholar
  4. 4.
    Widiger TA. Assessment of DSM-5 personality disorder. J Pers Assess. 2015;97:456–66.CrossRefGoogle Scholar
  5. 5.
    Basson R, Wierman ME, Van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med. 2010;7:314–26.CrossRefGoogle Scholar
  6. 6.
    Boardman LA, Stockdale CK. Sexual pain. Clin Obstet Gynecol. 2009;52(4):682–90.CrossRefGoogle Scholar
  7. 7.
    Graziottin A, Gambini D, Bertolasi L. Genital and sexual pain in women. Handb Clin Neurol. 2015;130:395–412.CrossRefGoogle Scholar
  8. 8.
    Faubion SS, Rullo JE. Sexual dysfunction in women: a practical approach. Am Fam Physician. 2015;92:281–8.Google Scholar
  9. 9.
    Seehusen DA, Baird DC, Bode DV. Dyspareunia in women. Am Fam Physician. 2014;90:465–70.Google Scholar
  10. 10.
    Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, et al. Definitions/epidemiology/ risk factors for sexual dysfunction. J Sex Med. 2010;7:1598–607.CrossRefGoogle Scholar
  11. 11.
    Nunns D, Mandal D, Byrne M, et al. British Society for the Study of Vulval Disease (BSSVD) guideline group. Guidelines for the management of vulvodynia. Br J Dermatol. 2010;162:1180–5.CrossRefGoogle Scholar
  12. 12.
    Caruso S, Iraci M, Cianci S, Casella E, Fava V, Cianci A. Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. J Endocrinol Investig. 2015;38:1211–8.CrossRefGoogle Scholar
  13. 13.
    Ferrero S, Ragni N, Remorgida V. Deep dyspareunia: causes, treatments, and results. Curr Opin Obstet Gynecol. 2008;20:394–9.CrossRefGoogle Scholar
  14. 14.
    Borghi C, Dell’Atti L. Pelvic congestion syndrome: the current state of the literature. Arch Gynecol Obstet. 2016;293:291–301.CrossRefGoogle Scholar
  15. 15.
    Winer AG, Chakiryan NH, Mooney RP, Verges D, Ghanaat M, Allaeei A, et al. Secondary pelvic congestion syndrome: description and radiographic diagnosis. Can J Urol. 2014;21:7365–8.Google Scholar
  16. 16.
    Monfortea M, Mimounb S, Droupy S. Sexual pain disorders in females and males. Prog Urol. 2013;23:761–70.CrossRefGoogle Scholar
  17. 17.
    Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J. 2015;26:15–28.CrossRefGoogle Scholar
  18. 18.
    •• Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s sexual health and the North American Menopause Society. Menopause. 2014;21:1063–8 This study formally endorsed the new terminology--genitourinary syndrome of menopause (GSM) shared by the Boards of NAMS and ISSWSH. CrossRefGoogle Scholar
  19. 19.
    Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: evaluation, sequelae, and management. Am J Obstet Gynecol. 2016;215:704–11.CrossRefGoogle Scholar
  20. 20.
    Bachmann GA. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:888–902.CrossRefGoogle Scholar
  21. 21.
    Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017;92:1842–9.CrossRefGoogle Scholar
  22. 22.
    McLean L, Brooks K. What does electromyography tell us about dyspareunia? Sex Med Rev. 2017;5:282–94.CrossRefGoogle Scholar
  23. 23.
    • Caruso S, Cianci S, Amore FF, et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause. 2016;23:47–54 This study shows the efficacy of local vaginal estriol use on postmenopausal women with sexual disorders. CrossRefGoogle Scholar
  24. 24.
    Caruso S, Cianci S, Vitale SG, Matarazzo MG, Amore FF, Cianci A. Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause. 2017;24:900–7.CrossRefGoogle Scholar
  25. 25.
    Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH. A randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom. J Women's Health (Larchmt). 2018;27:231–7.CrossRefGoogle Scholar
  26. 26.
    Kroll R, Archer DF, Lin Y, Sniukiene V, Liu JH. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. Menopause. 2018;25:133–8.Google Scholar
  27. 27.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, et al. Lack of influence of dyspareunia on the beneficial effect of intravaginal Prasterone (Dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. J Sex Med. 2014;11:1766–85.CrossRefGoogle Scholar
  28. 28.
    Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015;22:950–63.CrossRefGoogle Scholar
  29. 29.
    Nappi RE, Cagnacci A, Becorpi AM, Nappi C, Paoletti AM, Busacca M, et al. Monurelle Biogel® vaginal gel in the treatment of vaginal dryness in postmenopausal women. Climacteric. 2017;20:467–75.CrossRefGoogle Scholar
  30. 30.
    Leonardo-Pinto JP, Benetti-Pinto CL, Cursino KR, Yela D. A Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017;211:108–11.CrossRefGoogle Scholar
  31. 31.
    Maiorana A, Incandela D, Parazzini F, Alio W, Mercurio A, Giambanco L, et al. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch Gynecol Obstet. 2017;296:429–33.CrossRefGoogle Scholar
  32. 32.
    Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015;18:233–40.CrossRefGoogle Scholar
  33. 33.
    Goldstein SW, Winter AG, Goldstein I. Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study. Sex Med. 2018;6:154–61.CrossRefGoogle Scholar
  34. 34.
    Caruso S, Cianci S, Cariola M, Fava V, Rapisarda AM, Cianci A. Effects of nutraceuticals on quality of life and sexual function of perimenopausal women. J Endocrinol Investig. 2017;40:27–32.CrossRefGoogle Scholar
  35. 35.
    Villa P, Amar ID, Bottoni C, Cipolla C, Dinoi G, Moruzzi MC, et al. The impact of combined nutraceutical supplementation on quality of life and metabolic changes during the menopausal transition: a pilot randomized trial. Arch Gynecol Obstet. 2017;296:791–801.CrossRefGoogle Scholar
  36. 36.
    Caruso S, Cianci S, Fava V, Rapisarda AMC, Cutello S, Cianci A. Vaginal health of postmenopausal women on nutraceutical containing equol. Menopause. 2018;25:430–5.Google Scholar
  37. 37.
    Roghaei MA, Tehrany HG, Taherian A, Koleini N. Effects of Letrozole compared with Danazol on patients with confirmed endometriosis: a randomized clinical trial. IJFS. 2010;4:67–72.Google Scholar
  38. 38.
    Neri M, Piras B, Paoletti AM, Vallerino V, Corda V, Ronchetti C, et al. Long-acting reversible contraception (LARC) with the intrauterine system with levonorgestrel (6 mcg/d): observational study on the acceptability, quality of life, and sexuality in Italian women. Gynecol Endocrinol. 2018;34:532–5.CrossRefGoogle Scholar
  39. 39.
    Caruso S, Cianci S, Vitale SG, Fava V, Cutello S, Cianci A. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. Eur J Contracept Reprod Health Care. 2018;23:24–31.CrossRefGoogle Scholar
  40. 40.
    Yucel N, Baskent E, Karamustafaoglu Balci B, Goynumer G. The levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis. Aust N Z J Obstet Gynaecol. 2018;58:560–3.  https://doi.org/10.1111/ajo.12773.CrossRefGoogle Scholar
  41. 41.
    Ibe C, Simon JA. Vulvovaginal atrophy: current and future therapies. J Sex Med. 2010;7:1042–50.CrossRefGoogle Scholar
  42. 42.
    Caruso S, Serra A, Grillo C, De Leo V, Maiolino L, Agnello C, et al. Prospective study evaluating olfactometric and rhinomanometric outcomes in postmenopausal women on 1 mg 17beta-estradiol and 2 mg drospirenone HT. Menopause. 2008;15:967–72.CrossRefGoogle Scholar
  43. 43.
    Rahn D, Carberry C, Sanses TV, Mamik M, Ward RM, Meriwether KV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124:1147–56.CrossRefGoogle Scholar
  44. 44.
    Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18:121–34.CrossRefGoogle Scholar
  45. 45.
    •• Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018;51:68–91 This study supports the use of several drugs for symptomatic endometriosis having similar magnitude of effect, in terms of pain relief, independently of the mechanism of action. CrossRefGoogle Scholar
  46. 46.
    Soe LH, Wurz GT, Kao CJ, DeGregorio MW. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Womans Health. 2013;5:605–11.Google Scholar
  47. 47.
    Paton DM. Ospemifene for the treatment of dyspareunia in postmenopausal women. Drugs Today (Barc). 2014;50:357–64.CrossRefGoogle Scholar
  48. 48.
    Fantasia HC. Treatment of dyspareunia secondary to vulvovaginal atrophy. Nurs Womens Health. 2014;18:237–41.CrossRefGoogle Scholar
  49. 49.
    Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014;11:487–97.CrossRefGoogle Scholar
  50. 50.
    McLendon AN, Clinard VB, Brock WC. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women. Pharmacotherapy. 2014;34:1050–60.CrossRefGoogle Scholar
  51. 51.
    •• Pinkerton JV, Kagan R. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opin Pharmacother. 2015;16:2703–14 This study highlights the treatment with Ospemifene of postmenopausal women having dyspareunia, particularly for those who have tried and failed over-the-counter options or do not want vaginal therapies. CrossRefGoogle Scholar
  52. 52.
    DeGregorio MW, Zerbe RL, Wurz GT. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids. 2014;90:82–93.CrossRefGoogle Scholar
  53. 53.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy and of the genitourinary syndrome of menopause. Menopause. 2016;23:243–56.CrossRefGoogle Scholar
  54. 54.
    Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89.CrossRefGoogle Scholar
  55. 55.
    Nappi RE, Benedetto C, Campolo F, Martella S, Tosti C, Cianci A, et al. Efficacy, tolerability and safety of a new medical device, Monurelle Biogel(®) vaginal gel, in the treatment of vaginal dryness: a randomized clinical trial in women of reproductive age. Eur J Obstet Gynecol Reprod Biol. 2016;203:82–8.CrossRefGoogle Scholar
  56. 56.
    Stefano S, Stavros A, Candiani M. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol. 2015;27:504–8.Google Scholar
  57. 57.
    • Pitsouni E, Grigoriadis T, Falagas ME, Salvatore S, Athanasiou S. Laser therapy for the genitourinary syndrome of menopause: a systematic review and meta-analysis. Maturitas. 2017;103:78–88 This study indicate that CO2-laser therapy may contribute to complete regression of dyspareunia and dryness and reestablishment of normal sexual function in postmenopausal women. CrossRefGoogle Scholar
  58. 58.
    Cruz VL, Steiner ML, Pompei LM, Strufaldi R, Fonseca FLA, Santiago LHS, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25:21–2.CrossRefGoogle Scholar
  59. 59.
    Simonelli C, Eleuteri S, Petruccelli F, Rossi R. Female sexual pain disorders: dyspareunia and vaginismus. Curr Opin Psychiatry. 2014;27:406–12.CrossRefGoogle Scholar
  60. 60.
    Rosen NO, Bergeron S, Leclerc B, Lambert B, Steben M. Woman and partner-perceived partner responses predict pain and sexual satisfaction in provoked vestibulodynia (PVD) couples. J Sex Med. 2010;7:3715–24.CrossRefGoogle Scholar
  61. 61.
    Smith KB, Pukall CF, Chamberlain SM. Sexual and relationship satisfaction and vestibular pain sensitivity among women with provoked vestibulodynia. J Sex Med. 2013;10:2009–23.CrossRefGoogle Scholar
  62. 62.
    Pazmany E, Bergeron S, Van Oudenhove L, et al. Body image and genital self image in premenopausal women with dyspareunia. Arch Sex Behav. 2013;42:999–1010.CrossRefGoogle Scholar
  63. 63.
    Rosenbaum TY. An integrated mindfulness-based approach to the treatment of women with sexual pain and anxiety: promoting autonomy and mind/body connection. Sex Relation Ther. 2013;28:20–8.CrossRefGoogle Scholar
  64. 64.
    Cherner R, Reissing ED. A psychophysiological investigation of sexual arousal in women with lifelong vaginismus. J Sex Med. 2013;10:1291–303.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of General Surgery and Medical Surgical Specialties, Group of Sexual ResearchUniversity of CataniaCataniaItaly
  2. 2.Gynecological Clinic of the Policlinico UniversitarioCataniaItaly

Personalised recommendations